Trials / Active Not Recruiting
Active Not RecruitingNCT03033927
Predicting Effective Therapy in Pancreatic Cancer
Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 74 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | CTC isolocation and analysis | Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay. |
Timeline
- Start date
- 2017-01-24
- Primary completion
- 2026-01-24
- Completion
- 2026-01-24
- First posted
- 2017-01-27
- Last updated
- 2025-05-13
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT03033927. Inclusion in this directory is not an endorsement.